NASDAQ: SNYSanofi Stock Forecast, Predictions & Price Target
Analyst price target for SNY
Based on 5 analysts offering 12 month price targets for Sanofi.
Min Forecast
$56.00+12.27%
Avg Forecast
$61.20+22.69%
Max Forecast
$69.00+38.33%
Should I buy or sell SNY stock?
Buy
Strong Buy
4 analysts 50.00%
Buy
0 analysts 0.00%
Hold
4 analysts 50.00%
Sell
0 analysts 0.00%
Strong Sell
0 analysts 0.00%
Forecast return on equity
Is SNY forecast to generate an efficient return?
Company
9.41%
Industry
55.96%
Market
-1.56%
SNY's Return on Equity is forecast to be low in 4 years (9.41%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is SNY forecast to generate an efficient return on assets?
Company
4.92%
Industry
15.11%
Market
11.47%
SNY is forecast to generate lower Return on Assets (4.92%) than the US Drug Manufacturers - General industry average (15.11%)
Forecast
SNY earnings per share forecast
What is SNY's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$3.49+211.43%
Avg 2 year Forecast
$3.87+245.36%
Avg 3 year Forecast
$4.31+285.12%
SNY's earnings are forecast to grow at an exceptional rate of 56.55% per year
Forecast
SNY revenue forecast
What is SNY's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$44.2B+17.50%
Avg 2 year Forecast
$46.5B+23.51%
Avg 3 year Forecast
$48.8B+29.60%
SNY's revenue is forecast to grow at a rate of 9.02% per year, which is not exceptional
Forecast
SNY earnings growth forecast
How is SNY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
56.55%
Industry
20.03%
Market
14.71%
SNY's earnings are forecast to grow faster (56.55% per year) than the US Drug Manufacturers - General industry average (20.03%)
Forecast
SNY's earnings are forecast to grow faster (56.55% per year) than the US market average (14.71%)
Forecast
SNY revenue growth forecast
How is SNY forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
9.02%
Industry
6.43%
Market
5.62%
SNY's revenues are forecast to grow faster (9.02% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
SNY's revenues are forecast to grow faster (9.02% per year) than the US market average (5.62%)
Forecast
Sanofi Stock Forecast FAQ
Is Sanofi Stock a good buy in 2019, according to Wall Street analysts?
The consensus among 8 Wall Street analysts covering (NASDAQ: SNY) stock is to Buy SNY stock.
Out of 8 analysts, 4 (50.00%) are recommending SNY as a Strong Buy, 0 (0.00%) are recommending SNY as a Buy, 4 (50.00%) are recommending SNY as a Hold, 0 (0.00%) are recommending SNY as a Sell, and 0 (0.00%) are recommending SNY as a Strong Sell.
What is SNY's Price Target?
According to 5 Wall Street analysts that have issued a 1 year SNY price target, the average SNY price target is $61.20, with the highest SNY stock price forecast at $69.00 and the lowest SNY stock price forecast at $56.00.
On average, Wall Street analysts predict that Sanofi's share price could reach $61.20 by Oct 13, 2021. The average Sanofi stock price prediction forecasts a potential upside of 22.69% from the current SNY share price of $49.88.
What is SNY's earnings growth forecast for 2020-2022?
(NASDAQ: SNY) Sanofi's forecast annual earnings growth rate of 56.55% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 20.03%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 14.71%.
Sanofi's earnings in 2019 is $2,806,000,000.On average, 5 Wall Street analysts forecast SNY's earnings for 2020 to be $4,344,144,895, with the lowest SNY earnings forecast at $4,159,817,646, and the highest SNY earnings forecast at $4,657,999,400. On average, 5 Wall Street analysts forecast SNY's earnings for 2021 to be $4,817,417,561, with the lowest SNY earnings forecast at $4,620,635,768, and the highest SNY earnings forecast at $5,044,090,259.
In 2022, SNY is forecast to generate $5,372,018,399 in earnings, with the lowest earnings forecast at $5,280,726,592 and the highest earnings forecast at $5,417,726,575.
What is SNY's revenue growth forecast for 2020-2022?
(NASDAQ: SNY) Sanofi's forecast annual revenue growth rate of 9.02% is forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 5.62%.
Sanofi's revenue in 2019 is $37,631,000,000.On average, 3 Wall Street analysts forecast SNY's revenue for 2020 to be $55,067,333,460,103, with the lowest SNY revenue forecast at $54,779,829,033,507, and the highest SNY revenue forecast at $55,374,010,411,503. On average, 3 Wall Street analysts forecast SNY's revenue for 2021 to be $57,886,901,451,398, with the lowest SNY revenue forecast at $57,279,069,893,343, and the highest SNY revenue forecast at $58,933,705,861,990.
In 2022, SNY is forecast to generate $60,741,694,629,063 in revenue, with the lowest revenue forecast at $59,713,846,034,211 and the highest revenue forecast at $61,403,765,725,586.
What is SNY's Earnings Per Share (EPS) forecast for 2020-2022?
(NASDAQ: SNY) Sanofi's current Earnings Per Share (EPS) is $1.12. On average, analysts forecast that SNY's EPS will be $3.49 for 2020, with the lowest EPS forecast at $3.34, and the highest EPS forecast at $3.74. On average, analysts forecast that SNY's EPS will be $3.87 for 2021, with the lowest EPS forecast at $3.71, and the highest EPS forecast at $4.05. In 2022, SNY's EPS is forecast to hit $4.31 (min: $4.24, max: $4.35).
What is SNY's forecast return on equity (ROE) for 2020-2023?
(NASDAQ: SNY) forecast ROE is 9.41%, which is considered weak.
What is SNY's forecast return on assets (ROA) for 2020-2023?
(NASDAQ: SNY) forecast ROA is 4.92%, which is lower than the forecast US Drug Manufacturers - General industry average of 15.11%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
